Krystal Biotech, Inc. Common Stock
KRYS
Jodie situation report
Krystal Biotech, Inc. Common Stock's move is being confirmed by its market group.
KRYS accounts for 19.8% of the group's measured movement across 8.4 effective names. raw member direction is mixed; 8 of 12 session-normalized paths align to the upside. Capital-flow agreement is 17%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
KRYS was the first measured mover. KRYS crossed its material path threshold at 15:35 ET. JAZZ, CLDX, IMNM followed.
- Revenue increased 31.9% versus the comparable filing period.
14 of 18 members in Biotech Rare Diseases are active. 0 of 8 disclosed connections are confirming.
- At least 12 of 18 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ROIV begins moving with the group.
Invalidation: The live read weakens if participation falls to 6 of 18 members or fewer.
Who this business touches
The relationships behind KRYS
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ALNYAlnylam Pharmaceuticals, Inc.partnerFeb 17, 2026 ▾
“These can be generally classified into four broad categories: • Gene Silencing Approaches: We are aware of two companies, Takeda Pharmaceutical Company Limited (in partnership with Arrowhead Pharmaceutical Inc.) and Novo Nordisk A/S (in partnership with Alnyl…”
BBIOBridgeBio Pharma, Inc.partnerFeb 17, 2026 ▾
“We are also aware of a recombinant-protein-based approach being developed by BridgeBio Pharma, Inc.’s affiliate company, Phoenix Tissue Repair.”
Depended on by
FDMT4D Molecular Therapeutics, Inc.competitorMar 18, 2026 ▾
“We consider our most direct competitors with respect to 4D-710 for the treatment of CF lung disease to be Vertex Pharmaceuticals Incorporated, which has several approved CFTR modulators, as well as other companies in preclinical/early-clinical development of…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 9 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
KRYS is currently a Participant in the organic co-movement group Biotech Rare Diseases. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.